Questions on clinical trials
In private, medical scientists will admit that therapeutic research has had a poor record over the past two decades. Far too many questions about the value of treatment that were being asked in the early 1960s remain unanswered. For rheumatologists the outstanding problem is whether any of the available drugs really do slow down the disease process in rheumatoid arthritis. Among the reasons that that question is still unanswered are the poor design of many clinical trials and the futile planning of many medical conferences. No one gains from and much time is wasted by meetings at which speakers read boring accounts of poor studies to audiences assembled for other motives, with little if any time for discussion.
Against that background, I was pleased to attend a meeting held at the London Hospital earlier this year (and now reported in a supplement' to the British Journal of Rheumatology).
The meeting had only a few, commendably brief papers and most of the participants' time was spent in small workshops. Furthermore, the final session produced some clear conclusions and some more general opinions.
As an editor faced each year with the task of reading and assessing dozens of clinical trials I found myself in strong agreement with Richard Peto: a good trial should ask an important question and answer it reliably. Peto, the "big wing" man of trial design, believes that most good trials need to be very large or to have a long period of treatment or bothan approach vindicated by the contrast between the inconclusive results of early, small trials of beta blockers in coronary heart disease and the clear evidence of a small but important effect that emerged from the massive later studies.
One of the main reasons that the beta blocker studies convinced the sceptics was that the measure chosen was deathas "objective" and "hard" an end point as anyone could want. Rheumatoid arthritis provides no such clear measure-indeed, as Verna Wright reminded the meeting, clinicians may all too easily spend years writing "doing well" in the notes of a patient who has become progressively more crippled before their eyes. What matters to patients is the effects on their daily life of their damaged joints, and the account by J F Fries of the Stanford Arthritis Center Health Assessment Questionnaire2 suggested that a self administered questionnaire may be one workable method of measuring the extent of an individual's disability and of repeating that assessment at intervals. Typical of the questions asked are "Are you able to open jars which have been previously opened ?" and "Are you able to bend down to pick up clothing from the floor ?" When combined with a scoring system a questionnaire of this kind gives a good measure of features of practical importance to the patient. Indeed, one of the conclusions reached at the meeting was that patients should be encouraged to take more part in deciding the objectives of treatment.
So the way forward for rheumatologists seems to lie in better designed, better organised trials, probably larger and multicentre, and certainly using assessment methods that are reproducible, simple, and relevant to the patients' problems. Clinicians in other disciplines might usefully ask themselves similar questions to those posed at the London Hospital. 
Latissimus dorsi reconstruction of the breast
The latissimus dorsi is a large triangular muscle taking its origin from the lower thoracic and lumbar vertebrae, and from the posterior crest of the ilium. As it sweeps along the posterior wall of the axilla to be inserted into the bicipital groove of the humerus the muscle narrows considerably. The skin overlying the latissimus dorsi muscle is adequately supplied by perforating blood vessels from the muscle itself, and, conveniently for reconstructive purposes, the dominant nerve and blood supply of the muscle (the subscapular neurovascular bundle) enters its deep surface in the axilla. These anatomical features make it possible for the whole muscle origin, with an 12 The final result will depend on the site of the mastectomy scar and the type of mastectomy performed. Transverse scars are more favourable than oblique scars, which in turn are better than vertical scars. The site of the skin island may be planned anywhere over the latissimus dorsi muscle and a variable amount of muscle may be included distal and lateral to the skin island, depending on the site of the scar and whether additional muscle is required to cover bare ribs or to reconstruct the anterior axillary fold. The shape of the skin island may be varied to fulfil the reconstructive requirements of the particular case, but whenever possible the line of skin closure on the back and all scars of the reconstructed breast should be included within the volume covered by the brassiere. The size of the prosthesis inserted deep to the flap will depend on the size of the opposite breast and the wishes of the patient, but contralateral reduction, augmentation, or dermal mastopexy may be required. The complications associated with endoprostheses include failure to achieve symmetry, prosthetic shift or encapsulation, and infection-extrusion. Many 
